POLE2

Across TCGA pan-cancer cohorts, POLE2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POLE2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POLE2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated POLE2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where POLE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.910	0.573	<.001	68	view →
PDAC	OS	Median	All	0.458	0.878	.003	32	view →
LUAD	OS	Quartile	All	0.338	0.780	.006	12	view →
GBM	DFS	Median	All	0.474	0.852	.005	9	view →
UCEC	OS	Median	All	0.932	1.000	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POLE2–LSCC (DFS)

Open the LSCC breakdown →